Moreover, women and men who initiate hormone therapy (aromatase inhibitor and androgen deprivation therapy) should be offered discussions and counselling, regarding the adverse late effects of certain cancer therapies on bone health, both before starting cancer treatment and in the survivorship period [24]. This evidence concerns the gene CYP19A1 and cancer.